Items related to Designing Multi-Target Drugs (RSC Drug Discovery)
Multi-target drug discovery (MTDD) is an emerging area of increasing interest to the drug discovery community. Drugs that modulate several targets have the potential for an improved balance of efficacy and safety compared to single targets agents. Although there are a number of marketed drugs that are thought to derive their therapeutic benefit by virtue of interacting with multiple targets, the majority of these were discovered accidentally. Written by world renowned experts, this is the first book to gather together knowledge and experiences of the rational discovery of multi-target drugs. It describes the current state of the art, the achievements and the challenges of the field and importantly the lessons learned by researchers to date and their application to future MTDD.
"synopsis" may belong to another edition of this title.
From the Back Cover:
This book is intended to provide an integrated and comprehensive overview of modern approaches to multi-target drug discovery (MTDD) and the state of our knowledge in the over-arching field of polypharmacology. Given the intense current interest in this field, the editors hope that the book will be of significant interest to medicinal and computational chemists in the commercial sector and in academia, as well as the wider drug discovery community. Many readers will already be aware of the serendipitous nature of the discovery of many existing multi-target drugs. In this book the editors focus on the rational and practical execution of MTDD. The chapters are written by widely recognized experts and opinion leaders in the field. The first challenge of MTDD is to identify biologically validated combinations of targets relevant to a disease state. However it is equally important that these disease relevant combinations are chemically tractable from a medicinal chemistry perspective. The book thus follows a natural thread from target identification and validation, through lead generation and lead optimisation, and finally to clinical development. A key feature of the book is a collection of seminal case studies chosen to illustrate the challenges and opportunities of MTDD. These include compounds at various stages of development from pre-clinical to marketed drugs.
About the Author:
Richard Morphy gained his BSc (1995) and PhD (1989; supervisor: Prof. David Parker) in Chemistry from University of Durham 1989-1995: Medicinal chemist at Celltech, Slough, UK working on oncology and inflammation projects 1995-to date: Section head / Senior Research Fellow at Organon/SPRI/MSD, Newhouse, Scotland working on CNS and CV projects. He has an extensive track record of research, publications and presentations in the area of multi-target drug discovery (MTDD). John Harris gained his BSc.(Chemistry, 1999) from University of Exeter; PhD (Chemistry, 1974) from Queen Mary College, University of London (Supervisor: Prof. B.C.L. Weedon FRS) Postdoc study 1973-1975 with Prof. C.W.Rees at University of Liverpool. 1975 - 1982 Medicinal Chemist at Wellcome Labs, Beckenham, working on cardiovascular projects. 1983-1988 Principal Scientist 1989 - 1995 Head of Cardiovascular Area, Wellcome UK. 1996 - 2008 Founder and CSO of BioFocus (now division of Galapagos); 2009 - to date, independent pharma/biotech consultant. Comprehensive track record of research, publications and presentations in the areas of enzyme inhibitors, prostaglandins, compound library design, kinase drug development in oncology, inflammation and CNS, and multi-targeted drug discovery.
"About this title" may belong to another edition of this title.
- PublisherRoyal Society of Chemistry
- ISBN 10 1849734917
- ISBN 13 9781849734912
- BindingDigital
(No Available Copies)
Search Books: Create a WantIf you know the book but cannot find it on AbeBooks, we can automatically search for it on your behalf as new inventory is added. If it is added to AbeBooks by one of our member booksellers, we will notify you!
Create a Want